We serve Chemical Name:4-(Piperidin-1-ylsulfonyl)benzoic acid CAS:10252-83-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-(Piperidin-1-ylsulfonyl)benzoic acid
CAS.NO:10252-83-2
Synonyms:4-piperidin-1-ylsulfonylbenzoic acid
Molecular Formula:C12H15NO4S
Molecular Weight:269.31700
HS Code:2935009090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:459.6ºC at 760mmHg
Density:1.364g/cm3
Index of Refraction:
PSA:83.06000
Exact Mass:269.07200
LogP:2.57810
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-piperidin-1-ylsulfonylbenzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-piperidin-1-ylsulfonylbenzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-piperidin-1-ylsulfonylbenzoic acid Use and application,4-piperidin-1-ylsulfonylbenzoic acid technical grade,usp/ep/jp grade.
Related News: The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said. 4-(Piperidin-1-ylsulfonyl)benzoic acid manufacturer The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said. 4-(Piperidin-1-ylsulfonyl)benzoic acid supplier The ban will be in place for up to 14 days, and is aimed at helping contain the spread of the Wuhan coronavirus. So far, there have been no confirmed coronavirus cases in New Zealand or any South Pacific island. 4-(Piperidin-1-ylsulfonyl)benzoic acid vendor Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). 4-(Piperidin-1-ylsulfonyl)benzoic acid factory The ban will be in place for up to 14 days, and is aimed at helping contain the spread of the Wuhan coronavirus. So far, there have been no confirmed coronavirus cases in New Zealand or any South Pacific island.
